• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Henry Schein Inc.

    5/29/24 4:16:59 PM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    SD 1 formsdconflictmineral.htm FORM SD 2023 formsdconflictmineral
     
     
     
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM SD
    Specialized Disclosure Report
    HENRY SCHEIN, INC.
    (Exact name of registrant as specified in its charter)
    DELAWARE
    0-27078
    11-3136595
    (State or other jurisdiction
    (Commission File
    (IRS Employer
    of incorporation)
    Number)
    Identification No.)
    135 DURYEA ROAD, MELVILLE,
     
    NEW YORK
    11747
    (Address of principal executive offices)
    (Zip Code)
    Kelly Murphy, Senior Vice
     
    President and General Counsel
    (631) 843-5500
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and
    provide the period to which the information in this form applies:
     
    [X] Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period
    from January 1, 2023 to December 31, 2023.
    Section 1 – Conflict Minerals Disclosure
    Item 1.01.
     
    Conflict Minerals Disclosure and Report
    This
     
    report
     
    for
     
    the
     
    calendar
     
    year
     
    ended
     
    December
     
    31,
     
    2023
     
    is
     
    presented
     
    to
     
    comply
     
    with
     
    Rule
    13p-1
     
    under
     
    the
     
    Securities
     
    Exchange
     
    Act
     
    of
     
    1934
     
    (the
     
    “Rule”).
     
    The
     
    Rule
     
    imposes
     
    certain
    reporting
     
    obligations
     
    on
     
    Securities
     
    and
     
    Exchange
     
    Commission
     
    registrants
     
    whose
     
    manufactured
    products contain conflict
     
    minerals which are necessary
     
    to the functionality
     
    or production of their
    products. Conflict
     
    Minerals are
     
    defined as
     
    cassiterite, columbite-tantalite,
     
    gold, wolframite,
     
    and
    their derivatives,
     
    which are
     
    limited to
     
    tin, tantalum,
     
    and tungsten.
     
    These requirements
     
    apply to
    registrants whatever the
     
    geographic origin of the
     
    Conflict Minerals and
     
    whether or not they
     
    fund
    armed conflict.
    If
     
    a
     
    registrant
     
    conducts
     
    a
     
    Reasonable
     
    Country
     
    of
     
    Origin
     
    Inquiry
     
    (“RCOI”)
     
    and
     
    determines
     
    that
    the conflict
     
    minerals originated
     
    from sources
     
    other than
     
    the Democratic
     
    Republic of
     
    the Congo
    or an
     
    adjoining country
     
    (the “Covered
     
    Countries”), or
     
    from recycled
     
    and scrap
     
    sources, they
     
    are
    required only to submit a Form SD, which describes the RCOI.
    Although
     
    a
     
    substantial
     
    percentage
     
    of
     
    the
     
    products
     
    we
     
    sell
     
    are
     
    purchased
     
    from
     
    third-party
    suppliers
     
    as
     
    finished
     
    products,
     
    we
     
    manufacture
     
    or
     
    contract
     
    with
     
    third
     
    parties
     
    to
     
    manufacture
     
    a
    portion of
     
    our product
     
    portfolio.
     
    We
     
    determined that
     
    certain of
     
    those products
     
    contain Conflict
    Minerals that are necessary to their functionality or production.
     
    To
     
    determine if the Conflict Minerals
     
    in our manufactured and other covered
     
    products originated
    from
     
    sources
     
    in
     
    the
     
    Covered
     
    Countries,
     
    we
     
    conducted
     
    a
     
    RCOI
     
    in
     
    good
     
    faith.
     
    We
     
    surveyed
     
    all
    known
     
    suppliers
     
    from
     
    whom
     
    we
     
    purchase
     
    materials
     
    containing
     
    the
     
    Conflict
     
    Minerals.
     
    Where
    such
     
    suppliers
     
    did
     
    not
     
    initially
     
    provide
     
    sufficient
     
    information,
     
    we
     
    used
     
    the
     
    Conflict
     
    Minerals
    Reporting
     
    Template
     
    (a
     
    supply
     
    chain
     
    survey
     
    designed
     
    to
     
    identify
     
    smelters
     
    and
     
    refiners
     
    that
    process
     
    the
     
    necessary
     
    Conflict
     
    Minerals
     
    contained
     
    in
     
    our
     
    products)
     
    to
     
    obtain
     
    the
     
    relevant
     
    data.
     
    All such suppliers provided to us one or more of the following:
     
    •
    the policy they have in place to not purchase any products containing Conflict Minerals
    originating from the Covered Countries;
    •
    confirmation that their suppliers have affirmed to them that they have not provided any
    materials containing Conflict Minerals originating from the Covered Countries; and/or
    •
    the name of the smelter from whom the product originated and we identified said
    smelter as certified Conflict-Free using the Conflict Free-Sourcing Initiative’s web-site
    listing of conflict-free smelters.
    As a result
     
    of our RCOI,
     
    we have no
     
    reason to believe
     
    that our necessary
     
    Conflict Minerals may
    have originated in the
     
    Covered Countries or failed
     
    to meet conflict-free sourcing
     
    or the Conflict-
    Free Smelter Program assessment protocols.
     
    This Form SD is publicly available at investor.henryschein.com.
     
    The website and information
    accessible through it are not incorporated into this document.
    Item 1.02.
     
    Exhibit
    Not applicable.
    Section 2 – Exhibits
    Item 2.01.
     
    Exhibits
    Not applicable.
     
     
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
    duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    HENRY SCHEIN, INC.
    By: /s/ Kelly Murphy
    Kelly Murphy
    Senior Vice President and General Counsel
    Dated: May 29, 2024
    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Henry Schein with a new price target

    Barclays initiated coverage of Henry Schein with a rating of Overweight and set a new price target of $86.00

    12/9/25 8:50:15 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00

    8/26/25 8:13:41 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein downgraded by Stifel with a new price target

    Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00

    7/25/25 8:58:32 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    SEC Filings

    View All

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    1/12/26 7:00:12 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Henry Schein Inc.

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    12/23/25 4:05:30 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    12/23/25 7:00:20 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Global Dist. & Tech. Albertini Andrea covered exercise/tax liability with 2,032 shares, decreasing direct ownership by 3% to 65,900 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/11/25 4:14:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    12/9/25 9:05:50 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Chairman, CEO Bergman Stanley M gifted 140 units of Common Stock par value $0.01 per shre and gifted 500 shares, decreasing direct ownership by 0.20% to 319,877 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    11/26/25 4:10:29 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry S

    1/22/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Record Third Quarter 2025 Financial Results and Raises Full Year Non-GAAP EPS Guidance

    Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results

    11/4/25 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast Third Quarter 2025 Conference Call on Tuesday, November 4, 2025, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its third quarter 2025 financial results before the stock market opens on Tuesday, November 4, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Sc

    10/21/25 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care